false
0001971387
0001971387
2026-11-16
2026-11-16
0001971387
us-gaap:CommonClassAMember
2026-11-16
2026-11-16
0001971387
us-gaap:WarrantMember
2026-11-16
2026-11-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
November 16, 2026
Date of Report (Date of
earliest event reported)
| Liminatus Pharma, Inc. |
| (Exact Name of Registrant as Specified in its Charter) |
| Delaware |
|
001-42626 |
|
93-2710748 |
| (State or other jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
| of incorporation) |
|
File Number) |
|
Identification No.) |
| 2251
Stern Goodman Street, Suite
E, Fullerton,
CA |
|
92833 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (213)
273-5453
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act |
| |
|
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act |
| |
|
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act |
| |
|
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act |
Securities registered pursuant to Section 12(b) of
the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock |
|
LIMN |
|
The Nasdaq Stock Market LLC |
| Warrants |
|
LIMNW |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth
company x
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events.
On November 16, 2026, Liminatus Pharma, Inc. (the
“Company”) appointed Eric Sunghee Kang as Chief Corporate Strategist of the Company, effective immediately. In this role,
Mr. Kang will report to Chris Kim, the Company’s Chief Executive Officer, and will assist the Company with its corporate finance
and capital markets strategy, including its financing transactions, and the development of new business initiatives, in consultation with
the Chief Executive Officer.
Eric Sunghee Kang, age 43, has been the Chief
Executive Officer of Quantinum Investment, an investment firm based in Seoul, Korea, since 2022, where he focuses on cross-border capital
markets transactions, including private investments in public equity (PIPE) and strategic investments in Nasdaq-listed companies. Mr.
Kang served as Head of Strategy and Finance of a Nasdaq-listed company in 2025, and also served as Chief Executive Officer of a Korean
asset management firm in 2021. Prior to that, Mr. Kang spent approximately 12 years with global financial institutions, beginning his
career as a Research Analyst in the Investment Banking Division of Morgan Stanley in Hong Kong, and subsequently serving as a Vice President
in the Korean Large Corporates team of the Corporate Banking division of HSBC and as a Director of Corporate Sales in the Financial Markets
division of ING Bank N.V., Seoul Branch. Mr. Kang received a Bachelor of Science in Business from the Leonard N. Stern School of Business
at New York University.
The Company believes that Mr. Kang’s extensive
experience in the U.S. and Asian capital markets and in cross-border financing transactions will be valuable to the Company as it pursues
additional financing and new business initiatives to enhance stockholder value.
Mr. Kang will not receive any compensation for
his services as Chief Corporate Strategist.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. |
|
Description |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: November 18, 2026 |
|
|
| |
|
|
| |
LIMINATUS PHARMA, INC. |
| |
|
|
| |
By: |
/s/ Chris Kim |
| |
Name: |
Chris Kim |
| |
Title: |
Chief Executive Officer |